This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): R597, RG597
Description: The first compound in Halozyme's and Roche's collaboration is a subcutaneous formulation of Herceptin, using Halozyme's recombinant human hyaluronidase technology to enhance subcutaneous delivery. The Enhanze technology works by reversibly breaking down hyaluronan, a gel-like substance, that forms a barrier in the tissues between cells under the skin.
Herceptin is a humanized monoclonal antibody for the treatment of Her-2 overexpressing metastatic breast cancer. The subcutaneous form of Herceptin will be a flat dose, whereas the dose for Herceptin is weight-based.
Roche and Genentech
In July 1998, Genentech entered into an agreement with Roche to provide Roche exclusive marketing rights outside of the U.S. for Herceptin. Under the agreement, Roche paid $40.0 million and has agreed to pay cash milestones tied to future product development activities, to contribute equally with the Genentech up to a maximum of $40.0 million on global development costs and to make royalty payments on product sales.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Roche and Halozyme
On December 6, 2006, Halozyme and Roche announced they entered into an agreement to apply Halozymes proprietary Enhanze Technology to Roches biological therapeutic...See full deal structure in Biomedtracker
Partners: Halozyme Therapeutics, Inc. PDL BioPharma, Inc.
Herceptin-rHuPH20 (Subcutaneous) News
Additional information available to subscribers only: